Key terms

About AIM

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AIM news

Yesterday 9:05am ET AIM ImmunoTech appoints Lapp as a consulting Medical Officer by TipRanks Apr 03 3:05pm ET Ampligen’s Prospects in Post-COVID Fatigue and Cancer Treatment: A Strong Buy Recommendation by TipRanks Apr 02 2:00am ET Navigating the Future: Aim Immunotech’s Challenge Against Rapid Tech Evolution in Pharma by TipRanks Mar 25 9:18am ET AIM ImmunoTech announces publication of findings from Ampligen study by TipRanks Mar 21 11:18am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 07 8:45am ET AIM ImmunoTech launches CEO Corner platform by TipRanks Feb 29 8:48am ET AIM ImmunoTech outlines recent progress across development pipeline by TipRanks Feb 20 4:44pm ET AIM ImmunoTech Secures $2.5 Million Funding and Debt Terms by TipRanks Feb 15 1:45pm ET Buy Rating Affirmed for AIM ImmunoTech Amidst Promising Trials and Product Pipeline Developments by TipRanks Feb 14 8:57am ET AIM ImmunoTech announces first subject dosed in Netherlands for Ampligen study by TipRanks Feb 10 4:20am ET AIM ImmunoTech Touts Ampligen’s Post-COVID Study Success by TipRanks Feb 08 8:53am ET AIM ImmunoTech reports topline results from Phase 2 study of Ampligen by TipRanks Jan 26 4:52am ET AIM ImmunoTech Discloses Q1 Pancreatic Cancer Program Update by TipRanks Jan 24 9:12am ET AIM ImmunoTech receives Erasmus MC Ethics Board authorization by TipRanks Jan 22 8:57am ET AIM ImmunoTech enrolls first subject in Phase 1b/2 study of Ampligen by TipRanks

No recent press releases are available for AIM

AIM Financials

1-year income & revenue

Key terms

AIM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AIM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching
Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments